Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12014341 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL1404044 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL12014345 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL12014335 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL12014339 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL1403881 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL12014338 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL1404061 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL1403807 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD | |
| SCHEMBL12014344 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2KEAP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| CN-100349854-C | Method for producing (meth) acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| CN-100349851-C | Method for producing acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20240018132-A1 | 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER | GODAVARI BIOREFINERIES LTD. (IN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-115385892-A | Desloratadine derivative, preparation method and application thereof | 天津市昕晨投资发展有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-10174349-B2 | Recombinant cell producing 2-hydroxyisobutyric acid | EVONIK ROEHM GMBH (DE) | 2019-01-08 | — | — | US | disclosed |
| EP-2291530-B1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK ROEHM GMBH (DE) | 2018-12-26 | — | — | EP | disclosed |
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-0813529-A1 | ARGININE ANALOGUES HAVING NITRIC OXIDE SYNTHASE INHIBITOR ACTIVITY | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996027593-A1 | ARGININE ANALOGUES HAVING NITRIC OXIDE SYNTHASE INHIBITOR ACTIVITY | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1996-09-12 | — | — | WO | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0289262-A2 | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-11-02 | — | — | EP | disclosed |
| US-4455168-A | CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE | RICOH COMPANY, LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| US-4005085-A | SEDATIVES, ANTI-CONVULSANTS, MUSCLE RELAXANTS AND ANXIOLYTIC ACTIVITIES | HOFFMANN-LA ROCHE INC. (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018132-A1 | 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER | HSD17B11, HSD17B1, HSD3B1 | KDM4E 461/4885ALDH1A1 14/4885SMN1; SMN2 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.